PodParley PodParley
PodParley
MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated episode artwork

EPISODE · Apr 15, 2022 · 13 MIN

MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated

from MPR Weekly Dose

This week: the halting of the sabizabulin trial in COVID-19; Emergency Use Authorization to be requested for booster dose in 5 to 11 year olds; Diversity in Clinical Trials; Myopericarditis risk compared for COVID-19 vaccines vs other vaccines; And survey results of unvaccinated attitudes following FDA approval.

Episode metadata supplied by the publisher feed · Published Apr 15, 2022

Embed this episode

Ready to play

MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated

0:00 13:01

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 13 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on April 15, 2022.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!